Sweden's SynAct Pharma Q4 net loss widens as expenses rise

Reuters

Yesterday

Sweden's SynAct Pharma Q4 net loss widens as expenses rise

Overview

Sweden-based biotech firm's Q4 net sales were zero, consistent with clinical focus
Operating expenses rose 9% in Q4, contributing to a net loss of SEK 22.9 mln
Company initiated Phase 2 study in respiratory insufficiency post-Q4

Outlook

SynAct Pharma did not provide specific financial guidance for 2026

Result Drivers

CLINICAL DEVELOPMENT - SynAct Pharma focused on advancing resomelagon (AP1189) for inflammatory diseases, with 190 patients randomized in Phase 2b study
MANAGEMENT CONFIDENCE - Management and Chairman acquired shares and entered lock-up agreements, indicating confidence in the company's future
PHASE 2 STUDY INITIATION - Post-Q4, SynAct initiated a Phase 2 study in respiratory insufficiency

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales		SEK 0
Q4 Adjusted EPS		-SEK 0.43
Q4 Net Income		-SEK 22.93 mln
Q4 Cash Flow From Operating Activities		-SEK 23.97 mln
Q4 Operating Expenses		SEK 22.72 mln

Analyst Coverage

Wall Street's median 12-month price target for SynAct Pharma AB is SEK26.00, about 45.9% above its February 17 closing price of SEK17.82

Press Release: ID:nMFN8rR9s7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2612415579"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612415579\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612415579?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-18 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612415579","market":"fut","top_or_hot":-1,"title":"Sweden's SynAct Pharma Q4 net loss widens as expenses rise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's SynAct Pharma Q4 net loss widens as expenses rise</title></head><body><p><span>Overview</span></p><ul><li><p>Sweden-based biotech firm's Q4 net sales were zero, consistent with clinical focus</p></li><li><p>Operating expenses rose 9% in Q4, contributing to a net loss of SEK 22.9 mln</p></li><li><p>Company initiated Phase 2 study in respiratory insufficiency post-Q4</p></li></ul><p><span>Outlook</span></p><ul><li><p>SynAct Pharma did not provide specific financial guidance for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL DEVELOPMENT - SynAct Pharma focused on advancing resomelagon (AP1189) for inflammatory diseases, with 190 patients randomized in Phase 2b study</p></li><li><p>MANAGEMENT CONFIDENCE - Management and Chairman acquired shares and entered lock-up agreements, indicating confidence in the company's future</p></li><li><p>PHASE 2 STUDY INITIATION - Post-Q4, SynAct initiated a Phase 2 study in respiratory insufficiency</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td></td><td><p>SEK 0</p></td><td></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td></td><td><p>-SEK 0.43</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-SEK 22.93 mln</p></td><td></td></tr><tr><td><p>Q4 Cash Flow From Operating Activities</p></td><td></td><td><p>-SEK 23.97 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>SEK 22.72 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for SynAct Pharma AB is SEK26.00, about 45.9% above its February 17 closing price of SEK17.82</p></li></ul><p>Press Release: <span>ID:nMFN8rR9s7</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's SynAct Pharma Q4 net loss widens as expenses rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's SynAct Pharma Q4 net loss widens as expenses rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-18 14:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's SynAct Pharma Q4 net loss widens as expenses rise</title></head><body><p><span>Overview</span></p><ul><li><p>Sweden-based biotech firm's Q4 net sales were zero, consistent with clinical focus</p></li><li><p>Operating expenses rose 9% in Q4, contributing to a net loss of SEK 22.9 mln</p></li><li><p>Company initiated Phase 2 study in respiratory insufficiency post-Q4</p></li></ul><p><span>Outlook</span></p><ul><li><p>SynAct Pharma did not provide specific financial guidance for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CLINICAL DEVELOPMENT - SynAct Pharma focused on advancing resomelagon (AP1189) for inflammatory diseases, with 190 patients randomized in Phase 2b study</p></li><li><p>MANAGEMENT CONFIDENCE - Management and Chairman acquired shares and entered lock-up agreements, indicating confidence in the company's future</p></li><li><p>PHASE 2 STUDY INITIATION - Post-Q4, SynAct initiated a Phase 2 study in respiratory insufficiency</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td></td><td><p>SEK 0</p></td><td></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td></td><td><p>-SEK 0.43</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-SEK 22.93 mln</p></td><td></td></tr><tr><td><p>Q4 Cash Flow From Operating Activities</p></td><td></td><td><p>-SEK 23.97 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>SEK 22.72 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for SynAct Pharma AB is SEK26.00, about 45.9% above its February 17 closing price of SEK17.82</p></li></ul><p>Press Release: <span>ID:nMFN8rR9s7</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01049","symbol_name":"时富投资","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nL1N3ZE06I:1","article_id":"2612415579","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612415579","pubTimestamp":1771396649,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's SynAct Pharma Q4 net loss widens as expenses riseOverviewSweden-based biotech firm's Q4 net sales were zero, consistent with clinical focusOperating expenses rose 9% in Q4, contributing to a ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01049":"时富投资","BK1201":"家庭装饰零售"},"translate_title":"随着费用上升，瑞典SynAct Pharma第四季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01049":0.9},"content_text":"Sweden's SynAct Pharma Q4 net loss widens as expenses riseOverviewSweden-based biotech firm's Q4 net sales were zero, consistent with clinical focusOperating expenses rose 9% in Q4, contributing to a net loss of SEK 22.9 mlnCompany initiated Phase 2 study in respiratory insufficiency post-Q4OutlookSynAct Pharma did not provide specific financial guidance for 2026Result DriversCLINICAL DEVELOPMENT - SynAct Pharma focused on advancing resomelagon (AP1189) for inflammatory diseases, with 190 patients randomized in Phase 2b studyMANAGEMENT CONFIDENCE - Management and Chairman acquired shares and entered lock-up agreements, indicating confidence in the company's futurePHASE 2 STUDY INITIATION - Post-Q4, SynAct initiated a Phase 2 study in respiratory insufficiencyKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesSEK 0Q4 Adjusted EPS-SEK 0.43Q4 Net Income-SEK 22.93 mlnQ4 Cash Flow From Operating Activities-SEK 23.97 mlnQ4 Operating ExpensesSEK 22.72 mlnAnalyst CoverageWall Street's median 12-month price target for SynAct Pharma AB is SEK26.00, about 45.9% above its February 17 closing price of SEK17.82Press Release: ID:nMFN8rR9s7For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}